Reviewer’s report

Title: Cost-effectiveness Analysis of Anidulafungin for the Treatment of Candidaemia and Other Forms of Invasive Candidiasis

Version: 2 Date: 4 May 2015

Reviewer: FRANCESCO CATTEL

Reviewer’s report:

Regarding the part on METHODS: analysis took into account the perspective of the English health system, personnel Health and Human Services. (Advanced)

The population included in the analysis were non-neutropenic patients with an age> 16 and diagnosis of CI who already received a first-line treatment.

The model is quite complex in the decision is not taken into account what may be stopping treatment due to toxicity and various branch of survival does not indicate the clinical course after treatment, maybe because six weeks is a period too short. As regards the costs are not made explicit as individual unit costs but are considered in its overall to patient.

Profit would have been set over varying probabilistic sensitivity analysis also estimates the costs of clinical success and mortality because as already mentioned in the conclusions by the authors is too limiting as equivalent bring the chances of success and death from all echinocandins.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

'I declare that I have no competing interests' below